

Drug	Phase 1	Phase 2	Phase 3	Indication
BGB-3245 (BRAF inhibitor)				Advanced solid tumors with BRAF mutations
Lifirafenib (RAF inhibitor) + Mirdametinib (MEK inhibitor)				Advanced solid tumors
Ociperlimab (anti-TIGIT) + Tislelizumab (anti-PD-1)				1L PD-L1 high advanced NSCLC
				2L PD-L1+ advanced ESCC
				2L+ cervical cancer
				Advanced solid tumors
Ociperlimab + Tislelizumab + BAT1706 (anti-VEGF)				1L HCC
Ociperlimab + Tislelizumab + Chemotherapy				1L NSCLC
Ociperlimab + Tislelizumab + Concurrent Chemoradiotherapy				Previously untreated, stage III unresectable NSCLC
				Previously untreated LS-SCLC
Pamiparib (PARP 1/2 inhibitor)				2L/3L maintenance platinum-sensitive OC
				1L maintenance platinum-sensitive GC
				Advanced OC and TNBC
Pamiparib + Temozolomide				Advanced solid tumors
Tislelizumab				2L advanced ESCC
				1L HCC
				2L/3L NSCLC
				Previously treated unresectable HCC
				1L MSI-H or dMMR CRC
				Previously treated advanced MSI-high or dMMR solid tumors
Tislelizumab + Surzubiclimab (anti-TIM-3)				Advanced solid tumors
Tislelizumab + BGB-A445 (anti-OX40)				Advanced solid tumors
Tislelizumab + BGB-10188 (PI3Kδ inhibitor)				Advanced solid tumors
Tislelizumab + BGB-15025 (HPK1 inhibitor)				Advanced solid tumors

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BRAF, B-Raf proto-oncogene; CRC, colorectal cancer; dMMR, mismatch repair deficient; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HER2-, human epidermal growth factor receptor-2-negative; HPK1, hematopoietic progenitor kinase 1; LS-SCLC, limited-stage small cell lung cancer; MSI, microsatellite instability; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; OC, ovarian cancer; PD-L1: programmed death ligand-1; TIGIT: T-cell immunoreceptor with Ig and ITIM domains; TNBC, triple-negative breast cancer.



Drug	Phase 1	Phase 2	Phase 3	Indication
Tislelizumab + Chemoradiotherapy	[Red bar]			Localized ESCC
Tislelizumab + Chemotherapy/ Chemoradiotherapy	[Red bar]			Resectable ESCC
Tislelizumab + Chemotherapy	[Dark blue bar]			1L advanced ESCC
	[Dark blue bar]			1L GC/GEJC
	[Red bar]			Resectable stage II or IIIA NSCLC
	[Purple bar]			1L advanced nasopharyngeal cancer
	[Red bar]			1L squamous NSCLC
	[Red bar]			1L non-squamous NSCLC
	[Red bar]			1L advanced UBC
	[Red bar]			1L ES-SCLC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy	[Light green bar]			1L/2L GC/GEJC
Tislelizumab + Fruquintinib (VEGFR inhibitor)	[Orange bar]			Advanced GC/GEJC, CRC, and NSCLC
	[Dark blue bar]			Advanced triple negative BC
Tislelizumab + Lenvatinib (VEGFR kinase inhibitor)	[Red bar]			1L HCC
	[Red bar]			Advanced solid tumors
Tislelizumab + Sitravatinib (multikinase inhibitor)	[Light blue bar]			Advanced NSCLC after anti-PD-(L)1 therapy
	[Red bar]			Advanced GC/GEJC/HCC
	[Light blue bar]			Advanced solid tumors
Tislelizumab + Surufatinib (VEGFR, FGFR, CSF-1R inhibitor)	[Dark blue bar]			Advanced solid tumors
Zanidatamab (anti-HER2 bispecific antibody)	[Dark blue bar]			2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab	[Orange bar]			1L HER2+ BC and 1L HER2+ GC/GEJC

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BTC, biliary tract cancer; CRC, colorectal cancer; CSF-1R, colony stimulating factor-1 receptor; DKK1, Dickkopf-1; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; GC, gastric cancer; GEJC, gastroesophageal junction carcinoma; HCC, hepatocellular carcinoma; HER2+, human epidermal growth factor receptor-2-positive; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; UBC, urothelial bladder cancer; VEGFR, vascular endothelial growth factor receptors.

